Advertisement
News
Advertisement

Pulmatrix pulls in $14M in Series B round

Mon, 08/15/2011 - 5:42am
Mass High Tech: The Journal of New England Technology

Pulmatrix Inc., a Lexington biotechnology company focused on respiratory diseases, has taken in $14 million in a Series B1 funding round, from all previous including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund.

According to a press release by the company, Pulmatrix will use the new funds to speed up getting its lead iCALM drug candidate, PUR118, through Phase 2A efficacy studies in a pair of diseases - chronic obstructed pulmonary disease (COPD) and cystic fibrosis (CF).

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading